Cellular Dormancy in Cancer - Mechanisms and Potential Targeting Strategies

키워드

참고문헌 (171)

1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Wang X, "Drug resistance and combating drug resistance in cancer", Cancer Drug Resist, 2, pp.141~160 (2019)
3. Ruth JR, "Cellular dormancy in minimal residual disease following targeted therapy", Breast Cancer Res, 23, pp.63~ (2021)
4. Tachtsidis A, "Minimal residual disease in breast cancer : an overview of circulating and disseminated tumour cells", Clin Exp Metastasis, 33, pp.521~550 (2016)
5. Kang Y, "Tumor cell dissemination : emerging biological insights from animal models and cancer patients", Cancer Cell, 23, pp.573~581 (2013)
6. Badia-Ramentol J, "Minimal residual disease, metastasis and immunity", Biomolecules, 11, pp.130~ (2021)
7. Mohme M, "Circulating and disseminated tumour cells : mechanisms of immune surveillance and escape", Nat Rev Clin Oncol, 14, pp.155~167 (2017)
8. Yeh AC, "Mechanisms of cancer cell dormancy : another hallmark of cancer?", Cancer Res, 75, pp.5014~5022 (2015)
9. Endo H, "Dormancy in cancer", Cancer Sci, 110, pp.474~480 (2019)
10. Goss PE, "Does tumour dormancy offer a therapeutic target?", Nat Rev Cancer, 10, pp.871~877 (2010)
11. Damen MP, "Targeting dormant tumor cells to prevent cancer recurrence", FEBS J, 288, pp.6286~6303 (2021)
12. Recasens A, "Targeting cancer cell dormancy", Trends Pharmacol Sci, 40, pp.128~141 (2019)
13. Sosa MS, "Mechanisms of disseminated cancer cell dormancy : an awakening field", Nat Rev Cancer, 14, pp.611~622 (2014)
14. Phan TG, "The dormant cancer cell life cycle", Nat Rev Cancer, 20, pp.398~411 (2020)
15. Aguirre-Ghiso JA, "Models, mechanisms and clinical evidence for cancer dormancy", Nat Rev Cancer, 7, pp.834~846 (2007)
16. Indraccolo S, "Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment", Proc Natl Acad Sci U S A, 103, pp.4216~4221 (2006)
17. Swann JB, "Immune surveillance of tumors", J Clin Invest, 117, pp.1137~1146 (2007)
18. Aqbi HF, "IFN-gamma orchestrates tumor elimination, tumor dormancy, tumor escape, and progression", J Leukoc Biol, 103, pp.1219~1223 (2018)
19. Correia AL, "Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy", Nature, 594, pp.566~571 (2021)
20. Liu Y, "Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-gamma-induced immunologic dormancy of tumor-repopulating cells", Nat Commun, 8, pp.15207~ (2017)
21. Muller-Hermelink N, "TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis", Cancer Cell, 13, pp.507~518 (2008)
22. Braumuller H, "T-helper-1-cell cytokines drive cancer into senescence", Nature, 494, pp.361~365 (2013)
23. Basu S, "Slow-cycling(dormant)cancer cells in therapy resistance, cancer relapse and metastasis", Semin Cancer Biol, 78, pp.90~103 (2022)
24. Santos-de-Frutos K, "When dormancy fuels tumour relapse", Commun Biol, 4, pp.747~ (2021)
25. Townson JL, "Dormancy of solitary metastatic cells", Cell Cycle, 5, pp.1744~1750 (2006)
26. Spiliotaki M, "Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy", Breast Cancer Res, 16, pp.485~ (2014)
27. Gilje B, "Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients", Breast Cancer Res Treat, 128, pp.137~146 (2011)
28. Kato TA, "Mitotic index analysis", Methods Mol Biol, 2519, pp.17~26 (2023)
29. Oki T, "A novel cell-cycle-indicator, mVenus-p27K-, identifies quiescent cells and visualizes G0-G1 transition", Sci Rep, 4, pp.4012~ (2014)
30. Moore N, "Slow-cycling therapy-resistant cancer cells", Stem Cells Dev, 21, pp.1822~1830 (2012)
31. Yumoto K, "A novel method for monitoring tumor proliferation in vivo using fluorescent dye DiD", Cytometry A, 85, pp.548~555 (2014)
32. Chauvistre H, "Persister state-directed transitioning and vulnerability in melanoma", Nat Commun, 13, pp.3055~ (2022)
33. Tario JD Jr, "Optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes", J Vis Exp, pp.e4287~ (2012)
34. Ebinger S, "Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia", Cancer Cell, 30, pp.849~862 (2016)
35. Preciado JA, "Method to isolate dormant cancer cells from heterogeneous populations", Methods Mol Biol, 2394, pp.19~29 (2022)
36. Pradhan S, "Engineered in vitro models of tumor dormancy and reactivation", J Biol Eng, 12, pp.37~ (2018)
37. Gu Y, "Exploiting mouse models to recapitulate clinical tumor dormancy and recurrence in breast cancer", Endocrinology, 163, pp.bqac055~ (2022)
38. Sosa MS, "ERK1", 2 and p38alpha, Clin Cancer Res, pp.2011, 17[DOI]
39. Aguirre-Ghiso JA, "ERK(MAPK)activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK)", Cancer Res, 63, pp.1684~1695 (2003)
40. Barney LE, "Tumor cell-organized fibronectin maintenance of a dormant breast cancer population", Sci Adv, 6, pp.eaaz4157~ (2020)
41. Rehman SK, "Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy", Cell, 184, pp.226~242 (2021)
42. Cho J, "RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse", J Clin Invest, 131, pp.e136779~ (2021)
43. Pranzini E, "Metabolic features of tumor dormancy : possible therapeutic strategies", Cancers(Basel), 14, pp.547~ (2022)
44. Valcourt JR, "Staying alive : metabolic adaptations to quiescence", Cell Cycle, 11, pp.1680~1696 (2012)
45. Ranganathan AC, "Tumor cell dormancy induced by p38SAPK and ER-stress signaling : an adaptive advantage for metastatic cells?", Cancer Biol Ther, 5, pp.729~735 (2006)
46. Evertts AG, "H4K20 methylation regulates quiescence and chromatin compaction", Mol Biol Cell, 24, pp.3025~3037 (2013)
47. Milanovic M, "Senescence-associated reprogramming promotes cancer stemness", Nature, 553, pp.96~100 (2018)
48. Truskowski K, "Dormant cancer cells : programmed quiescence, senescence, or both?", Cancer Meta-stasis Rev, 42, pp.37~47 (2023)
49. Schmitt CA, "Senescence and cancer : role and therapeutic opportunities", Nat Rev Clin Oncol, 19, pp.619~636 (2022)
50. Iwasa H, "Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway", Genes Cells, 8, pp.131~144 (2003)
51. Prunier C, "Breast cancer dormancy is associated with a 4NG1 state and not senescence", NPJ Breast Cancer, 7, pp.140~ (2021)
52. Triana-Martinez F, "Beyond tumor suppression : senescence in cancer stemness and tumor dormancy", Cells, 9, pp.346~ (2020)
53. Saleh T, "Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy", Cancer Res, 79, pp.1044~1046 (2019)
54. Plaks V, "The cancer stem cell niche : how essential is the niche in regulating stemness of tumor cells?", Cell Stem Cell, 16, pp.225~238 (2015)
55. Desai A, "Concise reviews : cancer stem cell targeted therapies : toward clinical success", Stem Cells Transl Med, 8, pp.75~81 (2019)
56. Pattabiraman DR, "Tackling the cancer stem cells : what challenges do they pose?", Nat Rev Drug Discov, 13, pp.497~512 (2014)
57. Medema JP, "Cancer stem cells : the challenges ahead", Nat Cell Biol, 15, pp.338~344 (2013)
58. Lambert AW, "Linking EMT programmes to normal and neoplastic epithelial stem cells", Nat Rev Cancer, 21, pp.325~338 (2021)
59. Weidenfeld K, "EMT and stemness in tumor dormancy and outgrowth : are they intertwined processes?", Front Oncol, 8, pp.381~ (2018)
60. Mani SA, "The epithelial-mesenchymal transition generates cells with properties of stem cells", Cell, 133, pp.704~715 (2008)
61. Pradella D, "EMT and stemness : flexible processes tuned by alternative splicing in development and cancer progression", Mol Cancer, 16, pp.8~ (2017)
62. Wang SS, "Links between cancer stem cells and epithelial-mesenchymal transition", Onco Targets Ther, 8, pp.2973~2980 (2015)
63. Ocana OH, "Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1", Cancer Cell, 22, pp.709~724 (2012)
64. Jia Q, "Low Levels of Sox2 are required for melanoma tumor-repopulating cell dormancy", Theranostics, 9, pp.424~435 (2019)
65. Ohta Y, "Cell-matrix interface regulates dormancy in human colon cancer stem cells", Nature, 608, pp.784~794 (2022)
66. Zhou N, "Stem cell characteristics of dormant cells and cisplatin‑induced effects on the stemness of epithelial ovarian cancer cells", Mol Med Rep, 10, pp.2495~2504 (2014)
67. Fischer M, "Coordinating gene expression during the cell cycle", Trends Biochem Sci, 47, pp.1009~1022 (2022)
68. Giacinti C, "RB and cell cycle progression", Oncogene, 25, pp.5220~5227 (2006)
69. Kwon JS, "Controlling depth of cellular quiescence by an Rb-E2F network switch", Cell Rep, 20, pp.3223~3235 (2017)
70. Sadasivam S, "The DREAM complex : master coordinator of cell cycle-dependent gene expression", Nat Rev Cancer, 13, pp.585~595 (2013)
71. Litovchick L, "DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly", Genes Dev, 25, pp.801~813 (2011)
72. MacDonald J, "A systematic analysis of negative growth control implicates the DREAM complex in cancer cell dormancy", Mol Cancer Res, 15, pp.371~381 (2017)
73. Guiley KZ, "Structural mechanisms of DREAM complex assembly and regulation", Genes Dev, 29, pp.961~974 (2015)
74. Schade AE, "Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB", Oncogene, 38, pp.4962~4976 (2019)
75. Boichuk S, "The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis", Cancer Res, 73, pp.5120~5129 (2013)
76. Wang P, "Disrupting the DREAM complex enables proliferation of adult human pancreatic beta cells", J Clin Invest, 132, pp.e157086~ (2022)
77. Kim MJ, "PAF remodels the DREAM complex to bypass cell quiescence and promote lung tumorigenesis", Mol Cell, 81, pp.1698~1714 (2021)
78. Frantz C, "The extracellular matrix at a glance", J Cell Sci, 123, pp.4195~4200 (2010)
79. Yue B, "Biology of the extracellular matrix : an overview", J Glaucoma, 23(8 Suppl 1), pp.S20~3 (2014)
80. Hynes RO, "Overview of the matrisome : an inventory of extracellular matrix constituents and functions", Cold Spring Harb Perspect Biol, 4, pp.a004903~ (2012)
81. Naba A, "The extracellular matrix : Tools and insights for the"omics"era", Matrix Biol, 49, pp.10~24 (2016)
82. Winkler J, "Concepts of extracellular matrix remodelling in tumour progression and metastasis", Nat Commun, 11, pp.5120~ (2020)
83. Wei Y, "Regulation of integrin function by the urokinase receptor", Science, 273, pp.1551~1555 (1996)
84. Aguirre Ghiso JA, "Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling", J Cell Biol, 147, pp.89~104 (1999)
85. Aguirre-Ghiso JA, "Urokinase receptor and fibronectin regulate the ERK(MAPK)to p38(MAPK)activity ratios that determine carcinoma cell proliferation or dormancy in vivo", Mol Biol Cell, 12, pp.863~879 (2001)
86. Barkan D, "Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton", Cancer Res, 68, pp.6241~6250 (2008)
87. Barkan D, "Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment", Cancer Res, 70, pp.5706~5716 (2010)
88. Cho J, "The interplay between slow-cycling, chemoresistant cancer cells and fibroblasts creates a proinflammatory niche for tumor progression", Cancer Res, 80, pp.2257~2272 (2020)
89. Keeratichamroen S, "Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells", Oncol Rep, 39, pp.1765~1774 (2018)
90. Di Martino JS, "A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy", Nat Cancer, 3, pp.90~107 (2022)
91. Almog N, "Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype", Cancer Res, 69, pp.836~844 (2009)
92. Kazerounian S, "Thrombospondins in cancer", Cell Mol Life Sci, 65, pp.700~712 (2008)
93. Rouanne M, "Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer", BMC Cancer, 16, pp.483~ (2016)
94. Boyerinas B, "Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy", Blood, 121, pp.4821~4831 (2013)
95. Parker AL, "The role of the ECM in lung cancer dormancy and outgrowth", Front Oncol, 10, pp.1766~ (2020)
96. Rodrigues LR, "The role of osteopontin in tumor progression and metastasis in breast cancer", Cancer Epidemiol Biomarkers Prev, 16, pp.1087~1097 (2007)
97. Jiang Y, "Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy", J Hematol Oncol, 15, pp.34~ (2022)
98. Doue M, "Carbamylation of elastic fibers is a molecular substratum of aortic stiffness", Sci Rep, 11, pp.17827~ (2021)
99. Schrader J, "Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells", Hepatology, 53, pp.1192~1205 (2011)
100. Kondapaneni RV, "Matrix stiffness and cluster size collectively regulate dormancy versus proliferation in brain metastatic breast cancer cell clusters", Biomater Sci, 8, pp.6637~6646 (2020)
101. Anlas AA, "Soft microenvironments induce chemoresistance by increasing autophagy downstream of integrin-linked kinase", Cancer Res, 80, pp.4103~4113 (2020)
102. Liu Y, "Fibrin stiffness mediates dormancy of tumor-repopulating cells via a Cdc42-driven Tet2 epigenetic program", Cancer Res, 78, pp.3926~3937 (2018)
103. Sistigu A, "Tuning cancer fate : tumor microenvironment’s role in cancer stem cell quiescence and reawakening", Front Immunol, 11, pp.2166~ (2020)
104. Butturini E, "Tumor dormancy and interplay with hypoxic tumor microenvironment", Int J Mol Sci, 20, pp.4305~ (2019)
105. Ju S, "CSN8 is a key regulator in hypoxia-induced epithelial-mesenchymal transition and dormancy of colorectal cancer cells", Mol Cancer, 19, pp.168~ (2020)
106. Ameri K, "HIGD1A regulates oxygen consumption, ROS production, and AMPK activity during glucose deprivation to modulate cell survival and tumor growth", Cell Rep, 10, pp.891~899 (2015)
107. Bildik G, "DIRAS3 : an imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy, and tumor dormancy", Mol Cancer Ther, 21, pp.25~37 (2022)
108. Sutton MN, "Amino acid deprivation-induced autophagy requires upregulation of DIRAS3 through reduction of E2F1 and E2F4 transcriptional repression", Cancers(Basel), 11, pp.603~ (2019)
109. Wang L, "Autophagy mediates glucose starvation-induced glioblastoma cell quiescence and chemoresistance through coordinating cell metabolism, cell cycle, and survival", Cell Death Dis, 9, pp.213~ (2018)
110. Zhang M, "Nanog mediated by FAO", ACLY signaling induces cellular dormancy in colorectal cancer cells, 2022, pp.13, 159~
111. Dong X, "Modeling androgen deprivation therapy-induced prostate cancer dormancy and its clinical implications", Mol Cancer Res, 20, pp.782~793 (2022)
112. Kurppa KJ, "Treatment-induced tumor dormancy through YAP-mediated tran-scriptional reprogramming of the apoptotic pathway", Cancer Cell, 37, pp.104~122 (2020)
113. Min M, "Spontaneously slow-cycling subpopulations of human cells originate from activation of stress-response pathways", PLoS Biol, 17, pp.e3000178~ (2019)
114. Wagner EF, "Signal integration by JNK and p38 MAPK pathways in cancer development", Nat Rev Cancer, 9, pp.537~549 (2009)
115. Adam AP, "Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence", Cancer Res, 69, pp.5664~5672 (2009)
116. Sosa MS, "NR2F1 controls tumour cell dormancy via SOX9-and RARbeta-driven quiescence programmes", Nat Commun, 6, pp.6170~ (2015)
117. Cai B, "p38 MAP kinase mediates apoptosis through phosphorylation of BimEL at Ser-65", J Biol Chem, 281, pp.25215~25222 (2006)
118. Zhuang S, "p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide", J Biol Chem, 275, pp.25939~25948 (2000)
119. Sui X, "p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents", Cancer Lett, 344, pp.174~179 (2014)
120. Kroeger H, "The unfolded protein response regulator ATF6 promotes mesodermal differentiation", Sci Signal, 11, pp.eaan5785~ (2018)
121. Fu Y, "GRP78", BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis, 2007, pp.67, 3734~3740
122. Schewe DM, "ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo", Proc Natl Acad Sci U S A, 105, pp.10519~10524 (2008)
123. Gawrzak S, "MSK1 regulates luminal cell differentiation and metastatic dormancy in ER(+)breast cancer", Nat Cell Biol, 20, pp.211~221 (2018)
124. Aman Y, "Autophagy in healthy aging and disease", Nat Aging, 1, pp.634~650 (2021)
125. Akkoc Y, "Autophagy and cancer dormancy", Front Oncol, 11, pp.627023~ (2021)
126. Vera-Ramirez L, "Cell-intrinsic survival signals. The role of autophagy in metastatic dissemination and tumor cell dormancy", Semin Cancer Biol, 60, pp.28~40 (2020)
127. Chen Y, "Three dimensions of autophagy in regulating tumor growth : cell survival", death, cell proliferation, and tumor dormancy, 2021, pp.1867, 166265~
128. Gupta A, "Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor(GIST)", Proc Natl Acad Sci U S A, 107, pp.14333~14338 (2010)
129. Vera-Ramirez L, "Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence", Nat Commun, 9, pp.1944~ (2018)
130. Lu Z, "The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells", J Clin Invest, 118, pp.3917~3929 (2008)
131. Lu Z, "DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells", Autophagy, 10, pp.1071~1092 (2014)
132. Weiss A, "The TGFbeta superfamily signaling pathway", Wiley Interdiscip Rev Dev Biol, 2, pp.47~63 (2013)
133. Bragado P, "TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha", beta signalling, 2013, pp.15, 1351~1361
134. Yumoto K, "Axl is required for TGF-beta2-induced dormancy of prostate cancer cells in the bone marrow", Sci Rep, 6, pp.36520~ (2016)
135. Kobayashi A, "Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone", J Exp Med, 208, pp.2641~2655 (2011)
136. Pollak MN, "Insulin-like growth factors and neoplasia", Nat Rev Cancer, 4, pp.505~518 (2004)
137. Rajbhandari N, "Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of oncogenic drivers", Cell Rep, 18, pp.2243~2255 (2017)
138. Shimizu T, "IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress", Cancer Res, 74, pp.6531~6541 (2014)
139. Worster DT, "Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2", Sci Signal, 5, pp.ra19~ (2012)
140. Mercer TR, "Structure and function of long noncoding RNAs in epigenetic regulation", Nat Struct Mol Biol, 20, pp.300~307 (2013)
141. Ruksha TG, "MicroRNAs’ control of cancer cell dormancy", Cell Div, 14, pp.11~ (2019)
142. Nishikawa S, "Transcriptomic study of dormant gastrointestinal cancer stem cells", Int J Oncol, 41, pp.979~984 (2012)
143. Almog N, "Transcriptional changes induced by the tumor dormancy-associated microRNA-190", Transcription, 4, pp.177~191 (2013)
144. Vera-Ramirez L, "Tumor cell dormancy as an adaptive cell stress response mechanism", F1000Res, 6, pp.2134~ (2017)
145. Schonthal AH, "Endoplasmic reticulum stress : its role in disease and novel prospects for therapy", Scientifica(Cairo), 2012, pp.857516~ (2012)
146. Wang M, "The impact of the endoplasmic reticulum protein-folding environment on cancer development", Nat Rev Cancer, 14, pp.581~597 (2014)
147. Hetz C, "The unfolded protein response : controlling cell fate decisions under ER stress and beyond", Nat Rev Mol Cell Biol, 13, pp.89~102 (2012)
148. Lee K, "IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response", Genes Dev, 16, pp.452~466 (2002)
149. Maurel M, "Getting RIDD of RNA : IRE1 in cell fate regulation", Trends Biochem Sci, 39, pp.245~254 (2014)
150. Han J, "ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death", Nat Cell Biol, 15, pp.481~490 (2013)
151. Bartkowiak K, "Disseminated tumor cells persist in the bone marrow of breast cancer patients through sustained activation of the unfolded protein response", Cancer Res, 75, pp.5367~5377 (2015)
152. Pommier A, "Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases", Science, 360, pp.eaao4908~ (2018)
153. Ranganathan AC, "Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells", Cancer Res, 66, pp.1702~1711 (2006)
154. Jaud M, "Translational regulations in response to endoplasmic reticulum stress in cancers", Cells, 9, pp.540~ (2020)
155. Kehrl JH, "RGS2 : a multifunctional regulator of G-protein signaling", Int J Biochem Cell Biol, 34, pp.432~438 (2002)
156. Nguyen CH, "Translational control by RGS2", J Cell Biol, 186, pp.755~765 (2009)
157. Zmijewski JW, "Oxidative stress and heat shock stimulate RGS2 expression in 1321N1 astrocytoma cells", Arch Biochem Biophys, 392, pp.192~196 (2001)
158. Ota A, "Stress-induced transcription of regulator of G protein signaling 2(RGS2)by heat shock transcription factor HSF1", Biochimie, 95, pp.1432~1436 (2013)
159. Nguyen CH, "RGS2 is a component of the cellular stress response", Biochem Biophys Res Commun, 426, pp.129~134 (2012)
160. So-Yeon Park, "The force awakens: metastatic dormant cancer cells", Experimental and Molecular Medicine, 52, pp.1~13 (2020), 생화학분자생물학회[DOI]
161. Adamski V, "Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1", Oncogene, 39, pp.4421~4435 (2020)
162. Hirano R, "Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases", Commun Biol, 6, pp.144~ (2023)
163. Liu H, "Monocytic MDSC mobilization promotes tumor recurrence after liver transplantation via CXCL10", TLR4, Cell Death Dis, pp.2021, 12[DOI]
164. Albrengues J, "Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice", Science, 361, pp.eaao4227~ (2018)
165. Hast J, "Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice", Anticancer Res, 22, pp.677~688 (2002)
166. Cho J, "The ATF6-EGF pathway mediates the awakening of slow-cycling chemoresistant cells and tumor recurrence by stimulating tumor angiogenesis", Cancers(Basel), 12, pp.1772~ (2020)
167. Huang X, "Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma", Theranostics, 12, pp.5877~5887 (2022)
168. Bushnell GG, "Breast cancer dormancy : need for clinically relevant models to address current gaps in knowledge", NPJ Breast Cancer, 7, pp.66~ (2021)
169. Heidrich I, "Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors", Cancer Metastasis Rev, 42, pp.161~182 (2023)
170. Morin C, "Heterogeneity and dynamic of EMT through the plasticity of ribosome and mRNA translation", Biochim Biophys Acta Rev Cancer, 1877, pp.188718~ (2022)
171. Brown MS, "Phenotypic heterogeneity driven by plasticity of the intermediate EMT state governs disease progression and metastasis in breast cancer", Sci Adv, 8, pp.eabj8002~ (2022)

관련 논문AI추천